Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -25.09% is 83% above its 5-year average of -146.30%, near the high end of its 5-year range (-341.90%–-12.49%).
65.44% above its 12-month average of -72.59%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.31%.
RETURN ON ASSETS (ROA)
-25.09%
RETURN ON ASSETS (ROA) AVG TTM
-72.59%
RETURN ON ASSETS (ROA) AVG 3Y
-80.80%
RETURN ON ASSETS (ROA) AVG 5Y
-146.30%
RETURN ON ASSETS (ROA) AVG 10Y
-128.60%
RETURN ON ASSETS (ROA) AVG 15Y
-110.00%
RETURN ON ASSETS (ROA) AVG 20Y
-156.77%
CURRENT VS TTM AVG
+65.44%
CURRENT VS 3Y AVG
+68.95%
CURRENT VS 5Y AVG
+82.85%
CURRENT VS 10Y AVG
+80.49%
CURRENT VS 15Y AVG
+77.19%
CURRENT VS 20Y AVG
+84.00%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+22.18%
vs the sector median at left
Palisade Bio, Inc.
Market Cap
$258.63M
Return on Assets (ROA)
-25.09%
TTM Avg
-72.59%
3Y Avg
-80.80%
5Y Avg
-146.30%
Market Cap
$259.12M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$259.14M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$259.49M
Return on Assets (ROA)
-32.87%
TTM Avg
-28.32%
3Y Avg
-25.80%
5Y Avg
-21.10%
Market Cap
$259.56M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$256.47M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$261.27M
Return on Assets (ROA)
-35.62%
TTM Avg
-26.42%
3Y Avg
-45.47%
5Y Avg
-51.35%
Market Cap
$255.88M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$261.43M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palisade Bio, Inc. (PALI) | $258.63M | -25.09% | -72.59% | -80.80% | -146.30% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | -34.24% | -52.06% | -53.17% | -44.53% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | -35.96% | -58.88% | -82.10% | -113.46% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | -32.87% | -28.32% | -25.80% | -21.10% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -13.63% | -10.56% | -3.47% | -3.69% |
| AC Immune S.A. (ACIU)vs › | $256.47M | -29.15% | -33.84% | -33.85% | -31.54% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -35.62% | -26.42% | -45.47% | -51.35% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -2.06% | -16.77% | -17.09% | -12.28% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -37.07% | -27.27% | -64.53% | -52.03% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -45.18% | -124.83% | -176.38% | -195.56% |
ROA
-25.1%
ROE
-26.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -12.49% |
| 2024-12-31 | -132.70% |
| 2023-12-31 | -87.53% |
| 2022-12-31 | -90.47% |
| 2021-12-31 | -212.72% |
| 2020-12-31 | -341.90% |
| 2019-12-31 | -126.86% |
| 2018-12-31 | -64.09% |
| 2017-12-31 | -112.83% |
| 2016-12-31 | -93.23% |
| 2015-12-31 | -139.83% |
| 2014-12-31 | -75.82% |
| 2013-12-31 | -102.16% |
| 2012-12-31 | -115.68% |
| 2011-12-31 | -306.37% |
| 2010-12-31 | -173.60% |
| 2009-12-31 | -344.63% |
| 2008-12-31 | -216.34% |
| 2007-12-31 | -90.25% |
| 2006-12-31 | -162.84% |
| 2005-12-31 | -289.90% |
